F
F. Van Leth
Researcher at University of Amsterdam
Publications - 42
Citations - 2202
F. Van Leth is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Tuberculosis & Nevirapine. The author has an hindex of 22, co-authored 42 publications receiving 2094 citations.
Papers
More filters
Journal ArticleDOI
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F. Van Leth,Praphan Phanuphak,Kiat Ruxrungtham,E Baraldi,S Miller,Brian Gazzard,Pedro Cahn,Umesh G. Lalloo,IP van der Westhuizen,Malan,Margaret Johnson,B R Santos,Fiona Mulcahy,Robin Wood,GC Levi,G Reboredo,Kathleen Squires,I Cassetti,D Petit,François Raffi,Christine Katlama,Robert L. Murphy,Andrej Horban,JP Dam,Elly A. M. Hassink,R. Van Leeuwen,Patrick A. Robinson,F. W. Wit,Lange Jm +28 more
TL;DR: Antiretroviral therapy with nevirapine or efavirenz showed similar efficacy, so triple-drug regimens with either NNRTI are valid for first-line treatment, there are, however, differences in safety profiles.
Journal ArticleDOI
Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?
Eric Fontas,F. Van Leth,Caroline A. Sabin,Nina Friis-Møller,Martin Rickenbach,A d'Arminio Monforte,Ole Kirk,M Dupon,Linda Morfeldt,Silvia Mateu,Kathy Petoumenos,Wafaa El-Sadr,S De Wit,Jens D Lundgren,Christian Pradier,Peter Reiss +15 more
TL;DR: Patients receiving nonnucleoside reverse-transcriptase inhibitors had higher levels of TC and LDL-c than did antiretroviral-naive patients, although the risk of having lower HDL-c levels was lower than that in patients receiving a single PI.
Journal ArticleDOI
Measuring tuberculosis burden, trends, and the impact of control programmes.
Christopher Dye,A. Bassili,Ana Luiza Bierrenbach,JF Broekmans,Vineet K. Chadha,Philippe Glaziou,P. G. Gopi,Mehran Hosseini,S. J. Kim,Davide Manissero,Ikushi Onozaki,Hans L. Rieder,Suzanne Scheele,F. Van Leth,M J van der Werf,Brian G. Williams +15 more
TL;DR: Vbal autopsy, used in cause-of-death surveys, is an alternative, interim method of assessing tuberculosis mortality, but needs further validation, and the tuberculin skin test remains the only practical method of measuring infection in populations.
Journal ArticleDOI
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
F. Van Leth,S. Andrews,Beatriz Grinsztejn,Edmund Wilkins,M. K. Lazanas,J. M. A. Lange,Jsg Montaner +6 more
TL;DR: In this article, a post-hoc analysis within the randomized controlled 2NN trial comparing efficacy between regimes containing nevirapine (NVP), efavirenz (EFV), or both, in addition to stavudine and lamivudine.
Journal ArticleDOI
Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule
TL;DR: In this paper, the authors evaluate the validity of the fixed mathematical relationship between the annual risk of tuberculous infection (ARTI), the prevalence of smear-positive tuberculosis (TB) and the incidence of smear positive TB specified as the Styblo rule, which TB control programmes use to estimate the incidence at a population level and the case detection rate.